BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31999849)

  • 21. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
    Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
    Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance.
    Georgakopoulou R; Andrikopoulou A; Sergentanis TN; Fiste O; Zagouri F; Gavriatopoulou M; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):361-367. PubMed ID: 33582053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience.
    Alfano G; Fontana F; Colaci E; Messerotti A; Bettelli F; Potenza L; Luppi M; Cappelli G
    Transplantation; 2017 Nov; 101(11):e337-e342. PubMed ID: 28731904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
    Schmidt T; Callander N
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
    Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
    Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study.
    Ma L; Xu S; Qu J; Hou J; Wang Y; Wen L; Liu Y; Kang Y; Jiang M; Fu W; Du J; Zhou L; Huang X; Zhang Z; Lu J;
    Hematol Oncol; 2019 Feb; 37(1):75-79. PubMed ID: 30117173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal Gammopathy of Undetermined Significance.
    Gonsalves WI; Rajkumar SV
    Ann Intern Med; 2022 Dec; 175(12):ITC177-ITC192. PubMed ID: 36508741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
    Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).
    Cabrera Q; Macro M; Hebert B; Cornet E; Collignon A; Troussard X
    Cancer Epidemiol; 2014 Aug; 38(4):354-6. PubMed ID: 24880205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
    Rögnvaldsson S; Love TJ; Thorsteinsdottir S; Reed ER; Óskarsson JÞ; Pétursdóttir Í; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Eyþórsson E; Jónsson Á; Björnsson AS; Gunnarsson GÞ; Pálsson R; Indriðason ÓS; Gíslason GK; Ólafsson A; Hákonardóttir GK; Brinkhuis M; Halldórsdóttir SL; Ásgeirsdóttir TL; Steingrímsdóttir H; Danielsen R; Dröfn Wessman I; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY
    Blood Cancer J; 2021 May; 11(5):94. PubMed ID: 34001889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of monoclonal gammopathy of undetermined significance in Shenzhen, China.
    Xu A; Guo T; Zhang S; Luo H; Shen M; Ye Y; Ji L
    Hematology; 2024 Dec; 29(1):2352686. PubMed ID: 38819332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.
    Landgren O; Graubard BI; Kumar S; Kyle RA; Katzmann JA; Murata K; Costello R; Dispenzieri A; Caporaso N; Mailankody S; Korde N; Hultcrantz M; Therneau TM; Larson DR; Cerhan JR; Rajkumar SV
    Blood Cancer J; 2017 Oct; 7(10):e618. PubMed ID: 29053158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.
    Greenberg AJ; Rajkumar SV; Larson DR; Dispenzieri A; Therneau TM; Colby CL; Phelps TK; Kumar SK; Katzmann JA; Kyle RA; Slager SL; Vachon CM
    Br J Haematol; 2012 May; 157(4):472-5. PubMed ID: 22629552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying monoclonal gammopathy of undetermined significance in electronic health data.
    Epstein MM; Saphirak C; Zhou Y; LeBlanc C; Rosmarin AG; Ash A; Singh S; Fisher K; Birmann BM; Gurwitz JH
    Pharmacoepidemiol Drug Saf; 2020 Jan; 29(1):69-76. PubMed ID: 31736189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
    Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.
    Vachon CM; Kyle RA; Therneau TM; Foreman BJ; Larson DR; Colby CL; Phelps TK; Dispenzieri A; Kumar SK; Katzmann JA; Rajkumar SV
    Blood; 2009 Jul; 114(4):785-90. PubMed ID: 19179466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Monoclonal gammopathy of undetermined significance].
    Chaïbi P; Merlin L; Thomas C; Piette F
    Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Immunotyping Distribution of Serum Monoclonal Paraprotein and Environmental Impact on Multiple Myeloma (MM) and Monoclonal Gammopathy of Uncertain Significance (MGUS) in Taiwan: A Medical Center-Based Experience.
    Chang CC; Su MJ; Lee SJ; Tsai YH; Kuo LY; Lin IH; Huang HL; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2016; 17(1):395-9. PubMed ID: 26838245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.